AU2015256012B2 - VMAT2 inhibitors for the treatment of hyperkinetic movement disorders - Google Patents

VMAT2 inhibitors for the treatment of hyperkinetic movement disorders Download PDF

Info

Publication number
AU2015256012B2
AU2015256012B2 AU2015256012A AU2015256012A AU2015256012B2 AU 2015256012 B2 AU2015256012 B2 AU 2015256012B2 AU 2015256012 A AU2015256012 A AU 2015256012A AU 2015256012 A AU2015256012 A AU 2015256012A AU 2015256012 B2 AU2015256012 B2 AU 2015256012B2
Authority
AU
Australia
Prior art keywords
isoquinolin
dimethoxy
isobutyl
pyrido
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015256012A
Other languages
English (en)
Other versions
AU2015256012A1 (en
Inventor
Christopher F. O'Brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AU2015256012A1 publication Critical patent/AU2015256012A1/en
Application granted granted Critical
Publication of AU2015256012B2 publication Critical patent/AU2015256012B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2015256012A 2014-05-06 2015-05-06 VMAT2 inhibitors for the treatment of hyperkinetic movement disorders Active AU2015256012B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
AU2015256012A1 AU2015256012A1 (en) 2016-11-24
AU2015256012B2 true AU2015256012B2 (en) 2020-07-23

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015256012A Active AU2015256012B2 (en) 2014-05-06 2015-05-06 VMAT2 inhibitors for the treatment of hyperkinetic movement disorders

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3139925B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20160147044A (enExample)
CN (3) CN112741836A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3936130T3 (enExample)
ES (2) ES2976207T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20240459T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202400199T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075340A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
WO2018001335A1 (zh) * 2016-06-29 2018-01-04 苏州科睿思制药有限公司 Nbi-98854的晶型及其制备方法和用途
EP4400171A3 (en) * 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
AU2018241940B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited Dihydrotetrabenazine for use in the treatment a movement disorder
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
SG11202004165UA (en) * 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
AU2019261403B2 (en) * 2018-04-25 2025-05-15 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHOD OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
PH12021552745A1 (en) * 2019-05-09 2022-07-11 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Material Safety Data Sheet. Product Name Valbenazine tosylate. Published 01 May 2014 (see Revision date). Retrieved from internet 23 May 2020. URL: https://www.selleckchem.com/msds/MSDS_S9500.pdf *

Also Published As

Publication number Publication date
JP2017514850A (ja) 2017-06-08
SMT202200193T1 (it) 2022-07-21
ES2976207T3 (es) 2024-07-26
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
EP3936130A1 (en) 2022-01-12
RU2016147523A (ru) 2018-06-08
CN112741835A (zh) 2021-05-04
EP3139925A1 (en) 2017-03-15
US20200101063A1 (en) 2020-04-02
MX2016014429A (es) 2017-04-06
PL3139925T3 (pl) 2022-03-21
EP4389227A3 (en) 2024-09-04
JP2021191799A (ja) 2021-12-16
JP6635945B2 (ja) 2020-01-29
HRP20220025T1 (hr) 2022-04-01
KR20200133003A (ko) 2020-11-25
DK3139925T3 (da) 2021-12-20
RU2753740C2 (ru) 2021-08-23
CN112741836A (zh) 2021-05-04
PT3139925T (pt) 2022-01-26
NZ725826A (en) 2023-05-26
RS62782B1 (sr) 2022-01-31
CY1125058T1 (el) 2023-06-09
EP3936130B1 (en) 2024-02-14
HUE057839T2 (hu) 2022-06-28
LT3936130T (lt) 2024-04-25
KR20250029267A (ko) 2025-03-04
FI3936130T3 (fi) 2024-04-23
IL248745A0 (en) 2017-01-31
SI3936130T1 (sl) 2024-05-31
KR20160147044A (ko) 2016-12-21
CN106456629A (zh) 2017-02-22
KR20220140647A (ko) 2022-10-18
CA2947736A1 (en) 2015-11-12
EP4389227A2 (en) 2024-06-26
AU2015256012A1 (en) 2016-11-24
ES2904526T3 (es) 2022-04-05
KR20240011255A (ko) 2024-01-25
US20170071932A1 (en) 2017-03-16
PL3936130T3 (pl) 2024-06-10
IL248745B (en) 2022-07-01
US20210196702A1 (en) 2021-07-01
LT3139925T (lt) 2022-01-25
HUE066361T2 (hu) 2024-07-28
WO2015171802A1 (en) 2015-11-12
CA2947736C (en) 2023-04-18
JP2019218407A (ja) 2019-12-26
DK3936130T3 (da) 2024-03-25
JP2024153782A (ja) 2024-10-29
MX387625B (es) 2025-03-18
HRP20240459T1 (hr) 2024-06-21
PT3936130T (pt) 2024-04-17
RU2016147523A3 (enExample) 2018-12-28
SI3139925T1 (sl) 2022-04-29
RS65359B1 (sr) 2024-04-30

Similar Documents

Publication Publication Date Title
AU2015256012B2 (en) VMAT2 inhibitors for the treatment of hyperkinetic movement disorders
Moore et al. Tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
Kaye et al. Perioperative implications of common and newer psychotropic medications used in clinical practice
US20050096395A1 (en) Methods of treating attention deficit/hyperactivity disorder (adhd)
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)